Episode 40 of the AUPN Leadership Minute features Clifton L. Gooch, MD, of the University of South Florida; and Tom Frontera, MD, of the University of South Florida. [WATCH TIME: 9 minutes]
The president of the ANA and the chair of the annual meeting programming committee provided commentary on the advances in neurology and the shift in how clinicians approach and treat diseases once thought to be fatal. [WATCH TIME: 6 minutes]
There is no evidence yet that SARS-CoV-2 can pass the blood-brain barrier, though its effects on the barrier may be intensified in those with dementia.
The director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center discussed ways to build off the ARISE study and the unanswered questions regarding radiologically isolated syndrome. [WATCH TIME: 3 minutes]
Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population: Alzheimer disease and AD-related dementias.
The assistant professor of pharmacology at the University of Arizona College of Medicine Tucson shared her insight into the endocannabinoid system and its therapeutic potential in treating migraine. [WATCH TIME: 5 minutes]
At the 2023 MDA conference, the scientific research portfolio director at Muscular Dystrophy Association detailed a session on collaborative research in ALS and ongoing efforts in the field. [WATCH TIME: 3 minutes]
The associate professor of rehabilitation and regenerative medicine at Columbia University Medical Center discussed the ways clinicians go about properly prescribing exercise regimens for patients with spinal muscular atrophy. [WATCH TIME: 3 minutes]
The director of pharmacy at Emory Healthcare and Winship Cancer Institute talked about the role of pharmacists in multiple sclerosis patient care and collaborating with providers as biosimilars become available. [WATCH TIME: 5 minutes]
The professor of psychiatry and cell biology at NYU Langone provided commentary on new findings which challenge traditional theories on the root of Alzheimer disease and how it is targeted. [WATCH TIME: 17 minutes]
The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]
With many patients presenting with an unknown time of last known well, establishing a tissue window using advanced imaging techniques may allow for more effective intervention and better outcomes.
The division chief of pediatric neurosurgery at Ann & Robert H. Lurie Children's Hospital of Chicago talked about findings from a recently published study on long-term survival of pediatric patients with drug-resistant epilepsy which was presented at AES 2023. [WATCH TIME: 6 minutes]
The senior vice president of clinical development at Vaccinex provided commentary on a presentation from CTAD 2023 highlighting the therapeutic potential of peptinemab, an agent that’s shown success in Huntington disease, in patients with Alzheimer disease. [WATCH TIME: 3 minutes]
The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his investigations into improving the MSPT.
The director of research at St. Luke’s Sleep Medicine and Research Center discussed the current treatment landscape for excessive daytime sleepiness and how solriamfetol plays a role.
The expert neurologists discuss non-motor symptoms of Parkinson’s disease: types, their impact on patient’s quality of life, and current and emerging treatment options for non-motor symptoms.
Dr Andrew Charles shares how he eases patient anxieties over lifestyle changes for preventive migraine therapy.
At the 2023 MDA conference, a pediatric endocrinologist from Cincinnati Children’s Hospital talked about the unmet needs in treating bone health for patients with Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]
Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
Episode 13 of the AUPN Leadership Minute features Muhammad “Mud” Alvi, MD, of West Virginia University; and Barbara G. Vickrey, MD, MPH, of Icahn School of Medicine at Mount Sinai. [WATCH TIME: 4 minutes]
The chief executive officer of Cognito Therapeutics detailed clinical findings from the open-label extension of the phase 2 OVERTURE study presented at the recent Clinical Trials on Alzheimer’s Disease conference. [WATCH TIME: 4 minutes]
The director of medical outpatient services at the Kennedy Krieger Institute discussed the long-term effects of the updated developmental milestone guidelines and the need to judge children based on the 75th percentile. [WATCH TIME: 7 minutes]
The chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]
The director of neurocritical care and emergency neurology services at Westchester Medical Center Health System talked about a recently published paper that highlighted the need to address the disparity in quality metrics for stroke care, especially for intracerebral hemorrhage. [WATCH TIME: 4 minutes]